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Abstract 
Silencing of splicing regulators by RNA interference, combined with splicing-specific microarrays,
has revealed a complex network of distinct alternative splicing events in Drosophila, while a high-
throughput screen of more than 6,000 compounds has identified drugs that interfere specifically
and directly with one class of splicing regulators in human cells. 
Published: 1 December 2005
Genome Biology 2005, 6:240 (doi:10.1186/gb-2005-6-12-240)
The electronic version of this article is the complete one and can be
found online at http://genomebiology.com/2005/6/12/240
© 2005 BioMed Central Ltd 
The importance of splicing in the control of gene expression
is underscored by the realization that the human genome
codes for far fewer genes than expected [1]: we do not have
many more genes than the nematode Caenorhabditis elegans
and have fewer than the plant Arabidopsis thaliana. Alterna-
tive splicing, whereby regulated splice-site usage results in
the generation of different protein isoforms for the same gene
locus, is key to multiplying the diversity of proteins produced
from the human transcriptome. Computational alignments of
transcript data and high-throughput splicing-specific
microarray analyses have estimated that as many as 70% of
human genes undergo alternative splicing [2,3]. 
For most metazoan genes, an orchestra of around 100 pro-
teins and 5 small nuclear ribonucleoproteins performs the
daunting task of precisely excising introns and joining exons
together to produce the correct mature RNA product.
Because of the degeneracy of the branchpoint site and of the
classical 5 and 3 splice sites at the exon-intron boundaries,
additional cis-regulatory signals are used to aid exon detec-
tion. These signals are recognized by splicing regulators, the
most common of which are the serine-arginine-rich RNA-
binding proteins (SR proteins) and the heterogeneous
nuclear ribonucleoproteins (hnRNPs). These splicing regula-
tors modulate splice-site choice by interacting with compo-
nents of the splicing machinery and binding to the auxiliary
exonic and intronic cis-regulatory signals [4,5]. SR proteins
are thought to promote splice-site usage by associating with
exonic splicing enhancers [6]; hnRNPs, on the other hand,
act antagonistically to repress splice-site usage [7-9].
Current models of exon recognition suggest that the regula-
tors create a network of interactions that determines the
inclusion and exclusion of particular exons in transcripts.
Figure 1 illustrates the cooperative and antagonistic actions
of splicing regulators binding to interspersed regulatory ele-
ments in pre-mRNA transcripts. Given that the majority of
human genes contain introns and undergo alternative splic-
ing, mutations in cis-regulatory splicing elements or splice
sites have the potential to produce defective proteins and are
the cause of human genetic disorders such as spinal muscu-
lar atrophy, ataxia telangiectasia and thalassemia [10-14]. 
Complete genome sequences and microarray technology
have made possible the large-scale study of splicing and the
detection of alternatively spliced exons [2,15,16], but there is
still much to do to uncover the ‘splicing code’. This will
involve identifying the cis-acting elements in exons and
introns, identifying the regulators they bind, and understand-
ing their mode of action in different cell types and at various
developmental stages. Associations between regulators and
splicing events have traditionally been made by biochemical
and genetic methods. Although valuable, these methods are
slow and can only study one regulator or one splicing event at
a time. At present, a complete ‘mapping’ between regulators
and their target exons via cis-regulatory elements is not yet
available for any species. Such a map will be important in
revealing the mechanisms involved in context-dependent
inclusion and exclusion of alternative exons (as in differentcell types or developmental stages), as well as in the design
of low-toxicity drugs to alter splicing in the correction of
genetic disorders or to disrupt viral gene expression. Two
recent publications exemplify high-throughput and system-
atic strategies: Blanchette and colleagues [17] tackled the
identification of targets of four splicing regulators in
Drosophila melanogaster with a splicing-sensitive microarray,
while Soret et al. [18] screened for chemical compounds that
directly bind to SR proteins in human cells and interfere with
spliceosomal assembly. The application of these methods to
the study of more regulators and more compounds will pave
the way for future attempts to develop therapies for diseases
arising from aberrant splicing.
Analysis of splicing-regulator targets in
Drosophila
In order to identify the alternative splicing events controlled
by specific splicing regulators, Blanchette et al. [17] made
use of a recent experimental innovation - the combination of
the silencing of regulators with splicing-sensitive microarrays
to detect the effects. This technology has the potential not
only rapidly to identify the targets of these regulators
throughout the genome, but also to tease apart their combi-
natorial control. Blanchette et al. [17] investigated four well-
characterized and highly expressed splicing regulators - the
SR proteins dASF (Drosophila alternative splicing factor, the
homolog of human ASF, also known as splicing factor 2;
SF2) and B52 (the Drosophila equivalent of the mammalian
SRp55 protein) and the hnRNPs PSI and hrp48. They devel-
oped a splicing-sensitive microarray platform to monitor
around 3,000 annotated alternatively spliced genes in the
Drosophila  genome. As in other studies [2,15,19], oligo-
nucleotide probes were designed to span annotated alterna-
tively spliced junctions, with control probes across the
relevant constitutive junctions (that is, junctions that are
always spliced together) and within exons. In order to
silence the regulators by RNA interference (RNAi),
Drosophila  SL2 cells were treated with double-stranded
RNAs specific for each regulator gene. As these regulators
are likely to be associated not only with splicing but also with
other RNA-processing functions, Blanchette et al. [17] ini-
tially feared that a decrease in the levels of the regulators
might affect pre-mRNA processing in such a general manner
that the array data would be uninterpretable. Fortunately,
hierarchical clustering of multiple RNAi experiments
showed characteristic and reproducible splicing responses. 
The RNA isolated from the siRNA-treated cells was then
hybridized on the microarrays. Each regulator affected dis-
tinct sets of splice junctions, but the results revealed signifi-
cant overlap in the targets of dASF/SF2 and B52/SRp55,
consistent with the observation that SR proteins can comple-
ment one another on particular targets (see references cited
in [17]). The authors also observed that almost all the events
affected by PSI are also controlled by hrp48, suggesting that
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Figure 1
Splicing regulators and their targets. Four different genes are illustrated
on the left. Genes (a), (b) and (c) have two different splicing isoforms
each, as shown, while (d) is constitutively spliced. Exons are depicted by
the outlined boxes and introns by the straight lines connecting them. The
splicing regulators are depicted by the colored circles on the right, which
bind to the correspondingly colored cis-regulatory elements (upright
rectangles) in the exons and introns of the genes, promoting (+) or
repressing (-) the use of adjacent splice sites. The white circle and white
element represent unknown regulators and unidentified elements.
Different combinations of regulators result in differently spliced
transcripts, as represented by the zigzag lines joining exons. For example,
regulator I regulates the exclusion of alternative exons in (a) and (c).
Regulator II is required by regulator I, as indicated by the co-occurrences
of their cis-elements in introns near exons in genes (a) and (c), but
regulator II does not require regulator I, as in alternative 5 splice site
choice in (b), or mutually exclusive skipping of the first regulated exon in
(c). Binding of regulator III to its corresponding cis-element in (b)
promotes the inclusion of an additional exon.
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II
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IIIhrp48 is a required partner for PSI. Interestingly, this
relationship does not seem to be mutual, but further
experiments are necessary to confirm this finding. Figure 1
illustrates this scenario: regulator II is an obligatory partner
to I, but I is not required for II.
Consistent with the notion that dASF/SF2 is a general regu-
lator of alternative splicing, its knockdown affected the
largest number of events (319 events). Conversely, PSI, a
more specific regulator of alternative splicing, affected the
fewest events (43 events). In order to obtain evidence for
direct binding of B52/SRp55, a positional weight matrix of
an identified binding site for B52/SRp55 was used to scan
the exon-intron boundaries of splicing events affected by
knockdown of the factor. The motif was indeed specifically
over-represented at the 5 splice sites of exons at which
splicing is reduced when B52/SRp55 is knocked down.
Together, the findings revealed a network of tens to hun-
dreds of alternative splicing events that are regulated by
individual or combinations of splicing regulators. 
As acknowledged by Blanchette et al. [17], questions still
remain about why some targets are affected similarly by dif-
ferent regulators. There might be co-occurring binding sites
in the same set of exons, or the regulators might have over-
lapping binding specificities, or the regulators might be
interacting with another common regulator already present.
Knockdowns and overexpression of more splicing factors,
and parallel analyses of the sequence similarity of regulated
exons (and flanking introns), as well as the RNA binding
domain characteristics of the splicing regulators, should
clarify these questions.
Regulating the regulators with small-molecule
inhibitors
Various ways of correcting splicing defects have been sought.
Disease-associated exons can be induced to skip by antisense
oligonucleotides [20,21], or exon inclusion can be restored
by synthetic exon-specific effectors [22] or mediated by RNA
trans-splicing [23]. Although they are effective in correcting
the splicing defect, these methods are not readily adaptable
to high-throughput analysis with a view to finding drugs that
rescue aberrant splicing events.    
In another attempt to correct splicing defects, Sorel et al.
[18] investigated the inhibition of the recombinant SR
protein ASF/SF2 by small-molecule compounds. This
approach lends itself well to high-throughput methods. In
earlier work the authors had found that drugs interfering
with the kinase activity of topoisomerase I (topo I) affect the
phosphorylation status of SR proteins and prevent spliceo-
somal assembly (see reference cited in [18]). Building on
this, they screened 2,500 chemical compounds for the inhi-
bition of topo I phosphorylation of ASF/SF2, and obtained
28 potent inhibitors (Figure 2a). To determine whether these
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Figure 2
Screening strategies for small molecules that inhibit SR protein-mediated
splicing [18]. (a) Compounds were screened for their ability to inhibit
topoisomerase I phosphorylation of ASF/SF2, and then for repression of
splicing of reporter constructs. (b) Compounds were screened for
disruption of spliceosomal assembly, resulting in compounds that were
indole derivatives. (c) Indole derivatives were screened for selective
disruption of reporter pre-mRNAs where splicing was ASF/SF2 or SRp55
dependent. (d) Indole derivatives were screened for the ability to inhibit
aberrant splicing. See text for further details.
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 βcompounds selectively inhibit in vitro splicing of pre-mRNAs,
the authors tested these 28 compounds on two pre-mRNA
substrates: a synthetic single-intron pre-mRNA derived
from the adenovirus major late-transcription unit (Minx),
and a derivative of the human -globin gene that contains
three exonic splicing enhancers resembling a high-affinity
ASF/SF2-binding site (glo-3S). Three compounds had
strong inhibitory effects on glo-3S, whose splicing depends
on ESE sequences, but only one of the three affected Minx
pre-mRNA splicing, which is independent of ESE sequences
(Figure 2a). 
To determine which stage of spliceosome assembly was
affected, Soret et al. [18] then added 32P-labeled  glo-3S
pre-mRNA to HeLa nuclear extracts and incubated the
mixture with each of the three compounds. An early step of
assembly must have been disrupted, as no splicing com-
plexes were formed. Realizing that monitoring spliceosome
assembly would be a more straightforward way of identify-
ing compounds that affect splicing, the authors screened
1,500 small molecules and identified 25 candidates (Figure
2b). Surprisingly, these all have similar structures, being
indole derivatives of the pyridocarbazole, benzopyridoindole
or pyrido-pyrrolo-isoquinoline classes.
The next question was whether these compounds were tar-
geting ASF/SF2 directly, or the kinase activity of topo I
kinase, or both. Taking advantage of the strong intrinsic fluo-
rescence of one of the compounds, the authors found that it
interacted with ASF/SF2 directly rather than with topo I
(80% of drug fluorescence was quenched upon binding to
ASF/SF2). They found that while the overall structure of
ASF/SF2 is important, the RS domain of the protein is the
major drug-binding element. The RS domain contains the
repeated arginine (R)-serine (S) dipeptides that characterize
SR proteins. These domains are present not only in the SR
proteins but also in canonical splicing factors such as the U1-
snRNP-specific proteins U1-70K and U2AF. Their inhibition
could have effects on general RNA splicing and this empha-
sizes the importance of identifying all possible targets of
potential drugs to avoid problems of toxicity. Figure 3 illus-
trates three possible classes of drug, from the most poten-
tially toxic to the most specific and safest. 
In a subsequent experiment, Soret et al. [18] screened more
than 200 indole derivatives for their ability to inhibit the
splicing of glo-3S  by ASF/SF2 or the splicing of glo-
SRp55 by SRp55 (Figure 2c). In the latter construct, the
sequences with high affinity for ASF/SF2 have been replaced
by the optimal binding site for SRp55. Satisfyingly, they dis-
covered that some drugs are specific for one of the SR pro-
teins while some affected both. In a further experiment, they
created a gain-of-function mutation in HeLa cells, in which a
G-to-A change in an intron of the E1 pyruvate dehydroge-
nase (PDH) gene generates an ESE that binds the SR protein
SC35, and activates a cryptic 5 splice site downstream of the
mutation in the same intron. Consistent with indole deriva-
tives selectively inhibiting splicing depending on the SR pro-
teins involved, two drugs were shown to inhibit the use of
the cryptic splice site, presumably by affecting the binding of
SC35 (Figure 2d). The type of mutation created in PDH is
likely to be similar to splicing mutations that generate defec-
tive proteins in humans, and provides an avenue for thera-
peutic intervention (Figure 4).
As icing on the cake, Soret et al. [18] looked at the effects of
their indole derivatives on the splicing of the pre-mRNA of the
human immunodeficiency virus HIV-1. This pre-mRNA is reg-
ulated by alternative splicing involving SR proteins such as
ASF/SF2 and SC35. Chronically infected human promonocytic
U1 cell lines, which can be stimulated to produce large quanti-
ties of HIV-1 pre-mRNA, were treated with a number of indole
derivatives [18]. Several of these were shown specifically to
affect HIV-1 alternative splicing, and abolished HIV-1 virion
production. Neither cell viability nor the splicing profiles of
endogenous genes were affected, indicating the potentially low
toxicity of this treatment. This remarkable discovery opens new
approaches to treatment of HIV-1 infection by indole deriva-
tives via the interruption of ESE-mediated alternative splicing.
240.4 Genome Biology 2005, Volume 6, Issue 12, Article 240 Yeo http://genomebiology.com/2005/6/12/240
Genome Biology 2005, 6:240
Figure 3
Predicting the toxicity of drugs that affect splicing. Four genes with cis-
regulatory elements depicted as in Figure 1 are on the right, with the
corresponding splicing regulators symbolized as circles. Chemical
compounds are illustrated as cylinders on the left and are connected to
the regulator(s) with which they interfere. The most toxic drugs would
be those that affect a common regulator that binds to elements common
to many genes, for example, drug C affecting regulator V. Drugs that
affect several regulators with uncommon target elements would be less
toxic: for example, drug B interfering with regulators I, II, III, and IV. The
least toxic class would be drugs that specifically affect an uncommon
regulator, such as drug A affecting regulator III. 
Constitutive and alternative exons 
in protein-coding genes
Splicing 
regulators
Chemical 
compounds
+ − + + − +
− + + + +
+ + + + − −
+ + + + +
−
− −
I
II
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CThe studies of Blanchette et al. [17] and Soret et al. [18] are
the first large-scale screens for the genome-wide targets of a
small set of splicing regulators and for compounds that
disrupt a specific class of splicing regulators. One can envis-
age combining the power of the two methods. For example,
splicing-specific microarrays can query alternative splicing
events affected by particular compounds. Comparing these
events to alternative events affected by knockdowns of partic-
ular regulators may identify the candidate regulators affected
by the compounds. More comprehensive siRNA screens of
other RNA-binding proteins [24] using splicing-specific
microarrays could point to new roles for splicing modula-
tion. Looking forward, a large-scale mapping of regulators to
targets in humans, and of compounds to regulators, com-
bined with computational extraction of potential cis-regula-
tory binding sites, will be essential in the screening and
correction of splicing defects in human disease.
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Figure 4
Rescuing aberrant splicing with small-molecule drugs. (a) A gene that is
normally spliced with three exons is depicted in the top row. The filled
circles represent splicing regulators that act at the sites depicted by the
filled rectangles to promote splicing. Exons are depicted as outlined boxes.
The second row shows the effects of a G-to-A mutation in the downstream
intron that creates a binding site (filled rectangle named X) for a regulator
(circle Y) which activates a cryptic 5 splice site, leading to the splicing of an
additional sequence into the final mRNA and the production of a defective
protein. The third row shows the effects of therapy with a drug that
abolishes binding of the Y regulator and restores normal splicing. (b) A
drug (cylinder) that nonspecifically inhibits both regulator Y and other
common regulators will correct the effects of mutation X but will be more
toxic than a drug that inhibits only regulator Y.
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